Myocardial fibrosis pathway

The myocardial fibrosis pathway is a complex biological process characterized by the excessive accumulation of extracellular matrix (ECM) components, such as collagen, within the myocardium. This pathway is typically triggered by cardiac injury or chronic stress, leading to the activation of resident fibroblasts into myofibroblasts, which are the primary cells responsible for ECM production (PubMed: 29107023). Key molecular drivers include Transforming Growth Factor-beta (TGF-β), Angiotensin II, and Aldosterone, which stimulate signaling cascades that promote collagen synthesis and inhibit degradation (PubMed: 11523034). While initially serving as a reparative mechanism to replace necrotic myocytes, persistent activation of this pathway leads to increased ventricular stiffness, electrical remodeling, and progressive heart failure (PubMed: 30249488). Current therapeutic interventions focus on modulating the renin-angiotensin-aldosterone system (RAAS) to slow progression, while novel agents targeting specific nodes like Galectin-3 or TGF-β receptors are under investigation to directly reverse fibrotic changes (PubMed: 24508011). The pathway also involves inflammatory cytokines and matricellular proteins that modulate the microenvironment and influence the transition from acute inflammation to chronic fibrosis (PubMed: 26069257). Understanding the spatial and temporal regulation of this pathway is crucial for developing targeted anti-fibrotic therapies that do not interfere with essential wound healing processes.

Other names

Cardiac fibrosis pathwayMyocardial remodeling pathwayCardiac fibrotic signaling

Inhibition of pro-fibrotic signaling cascades, including the renin-angiotensin-aldosterone system (RAAS) and the TGF-beta/Smad pathway, to reduce myofibroblast activation and extracellular matrix deposition.